DASH vs RNAC · P/E 76, rev $13.72B vs P/E 2.1, rev $38.9M
DoorDash, Inc. Class A Common Stock (DASH) versus Cartesian Therapeutics Inc. (RNAC) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Cartesian Therapeutics Inc. (RNAC) is a biotechnology company listed on US.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Latest reported RNAC revenue for 2024-12-31 was $38.9M. Net income was -$77.4M. Revenue was up 49.6% from 2023-12-31 to 2024-12-31. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
Not investment advice. Open the DASH and RNAC stock pages for the full models.
Not investment advice.